Anti-BCMA chimeric antigen receptor NK-cell therapy(Takeda/The University of Texas MD Anderson Cancer Center)

N/A

Report date: 2024/01/02 16:36:18

Base Information

Drug NameAnti-BCMA chimeric antigen receptor NK-cell therapy(Takeda/The University of Texas MD Anderson Cancer Center)
Drug Alias NameAnti-BCMA CAR NK-cell therapy (Takeda/The University of Texas MD Anderson Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A